Page 145 - 2022_03-Haematologica-web

Patterns of genetic alterations in B-NHL
genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in the activat- ed B-cell subtype of diffuse large B-cell lym- phoma. Sci Transl Med. 2019;11(497): eeav5599.
27. Kim D, Fiske BP, Birsoy K, et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clear- ance. Nature. 2015;520(7547):363-367.
28. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3(2):185-197.
29. Salaverria I, Royo C, Carvajal-Cuenca A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) man- tle cell lymphoma. Blood. 2013;121(8): 1394-1402.
30. Green MR, Vicente-Duenas C, Romero- Camarero I, et al. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nat Commun. 2014;5:3904.
31. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
32. Saeki K, Miura Y, Aki D, Kurosaki T, Yoshimura A. The B cell-specific major raft protein, Raftlin, is necessary for the integri- ty of lipid raft and BCR signal transduction. EMBO J. 2003;22(12):3015-3026.
33. Senft D, Qi J, Ronai ZA. Ubiquitin ligases in oncogenic transformation and cancer thera- py. Nat Rev Cancer. 2018;18(2):69-88.
34. Monti S, Chapuy B, Takeyama K, et al. Integrative analysis reveals an outcome- associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012;22(3): 359-372.
35. Honma K, Tsuzuki S, Nakagawa M, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non- Hodgkin lymphomas. Blood. 2009;114(12): 2467-2475.
36. Hartmann EM, Campo E, Wright G, et al. Pathway discovery in mantle cell lym- phoma by integrated analysis of high-reso- lution gene expression and copy number profiling. Blood. 2010;116(6):953-961.
37. Choi J, Lee K, Ingvarsdottir K, et al. Loss of KLHL6 promotes diffuse large B-cell lym- phoma growth and survival by stabilizing the mRNA decay factor roquin2. Nat Cell Biol. 2018;20(5):586-596.
38. Meriranta L, Pasanen A, Louhimo R, et al. Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma. Haematologica. 2017;102(5):e195-e198.
39. Swenson SA, Gilbreath TJ, Vahle H, et al.
UBR5 HECT domain mutations identified in mantle cell lymphoma control matura- tion of B cells. Blood. 2020;136(3):299-312.
40.Mottok A, Renne C, Seifert M, et al. Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood. 2009;114(20):4503-4506.
41. Liu W, Quinto I, Chen X, et al. Direct inhi- bition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein. Nat Immunol. 2001;2 (10):939-946.
42. Pawar SA, Sarkar TR, Balamurugan K, et al. C/EBP{delta} targets cyclin D1 for protea- some-mediated degradation via induction of CDC27/APC3 expression. Proc Natl Acad Sci U S A. 2010;107(20):9210-9215.
43.Krysiak K, Gomez F, White BS, et al. Recurrent somatic mutations affecting B- cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017;129(4): 473-483.
44. Gloury R, Zotos D, Zuidscherwoude M, et al. Dynamic changes in Id3 and E-protein activity orchestrate germinal center and plasma cell development. J Exp Med. 2016;213(6):1095-1111.
45. Okosun J, Wolfson RL, Wang J, et al. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet. 2016;48(2):183-188.
46. Wang F, Gatica D, Ying ZX, et al. Follicular lymphoma-associated mutations in vacuo- lar ATPase ATP6V1B2 activate autophagic flux and mTOR. J Clin Invest. 2019;130: 1626-1640.
47. Hu J, Li L, Chen H, et al. MiR-361-3p regu- lates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma. Cell Death Dis. 2018;9 (8):807.
48.Lu D, Liu L, Ji X, et al. The phosphatase DUSP2 controls the activity of the tran- scription activator STAT3 and regulates TH17 differentiation. Nat Immunol. 2015;16(12):1263-1273.
49. Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551-568.
50. Lacy SE, Barrans SL, Beer PA, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020;135(20):1759-1771.
51. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419-2430.
52. Green MR. Chromatin modifying gene mutations in follicular lymphoma. Blood.
2018;131(6):595-604.
53. Balinas-Gavira C, Rodriguez MI, Andrades
A, et al. Frequent mutations in the amino- terminal domain of BCL7A impair its tumor suppressor role in DLBCL. Leukemia. 2020;34(10):2722-2735.
54. Yusufova N, Kloetgen A, Teater M, et al. Histone H1 loss drives lymphoma by dis- rupting 3D chromatin architecture. Nature. 2021;589(7841):299-305.
55. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell. 2011;145(1):30-38.
56. Beguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center for- mation and somatic EZH2 mutations pro- mote lymphoid transformation. Cancer Cell. 2013;23(5):677-692.
57. Garcia-Ramirez I, Tadros S, Gonzalez- Herrero I, et al. Crebbp loss cooperates with Bcl2 over-expression to promote lym- phoma in mice. Blood. 2017;129(19):2645- 2656.
58. Zhang J, Vlasevska S, Wells VA, et al. The Crebbp acetyltransferase is a haploinsuffi- cient tumor suppressor in B cell lymphoma. Cancer Discov. 2017;7(3):322-337.
59. Jiang Y, Ortega-Molina A, Geng H, et al. CREBBP inactivation promotes the devel- opment of HDAC3-dependent lym- phomas. Cancer Discov. 2017;7(1):38-53.
60. Zhang J, Dominguez-Sola D, Hussein S, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. 2015;21(10): 1190-1198.
61. Ortega-Molina A, Boss IW, Canela A, et al. The histone lysine methyltransferase KMT2D sustains a gene expression pro- gram that represses B cell lymphoma development. Nat Med. 2015;21(10):1199- 1208.
62. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298-303.
63. Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A. Emerging epigenetic- modulating therapies in lymphoma. Nat Rev Clin Oncol. 2019;16(8):494-507.
64. Shen M, Schmitt S, Buac D, Dou QP. Targeting the ubiquitin-proteasome system for cancer therapy. Expert Opin Ther Targets. 2013;17(9):1091-1108.
65. Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-mimetic drugs: blazing the trail for new cancer med- icines. Cancer Cell. 2018;34(6):879-891.
66. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11(1):12-23.
haematologica | 2022; 107(3)
701